Product Overview

Metsmall 1000 SR is a sustained‑release tablet formulated to help adults manage Type 2 diabetes mellitus. Each tablet contains 1000 mg of metformin, the first‑line oral agent recommended by major clinical guidelines. The product is manufactured by Dr Reddy’s Laboratories Ltd, a globally recognised pharmaceutical company with a strong track record in diabetes care. The tablets are packaged in strips of 15, with available pack sizes of 30, 60, and 90 tablets, providing flexibility for long‑term therapy. Metsmall 1000 SR is intended for oral use and should be stored at room temperature, away from moisture and direct sunlight. The medication is marketed as a convenient, once‑daily option that supports consistent glycaemic control when used alongside diet and exercise.

What is Metsmall 1000 SR (Metformin)

Metformin belongs to the biguanide class of antihyperglycaemic agents. It works primarily by decreasing hepatic glucose production and improving peripheral insulin sensitivity. Unlike immediate‑release formulations, the SR (slow‑release) coating allows the drug to be absorbed gradually, resulting in steadier plasma concentrations and a reduced risk of gastrointestinal upset. This formulation is especially beneficial for patients who experience side effects with standard metformin or who require a more consistent day‑long effect. The active ingredient is identical to that of generic metformin, but the SR technology differentiates Metsmall 1000 SR in terms of pharmacokinetics and dosing convenience. For detailed scientific background, you can explore resources from the National Institutes of Health (NIH).

Uses and Benefits

The primary indication for Metsmall 1000 SR is the treatment of Type 2 diabetes when lifestyle modification alone is insufficient. Clinical studies have demonstrated that metformin can lower HbA1c by 1–2 % on average, reduce fasting plasma glucose, and improve insulin sensitivity without causing weight gain. In addition, real‑world data suggest a potential cardiovascular benefit, including a lower incidence of myocardial infarction and mortality in diabetic patients. The sustained‑release design may improve adherence because it is taken once daily with the evening meal, allowing patients to maintain a stable therapeutic regimen. Furthermore, the medication is associated with a low risk of hypoglycaemia when used without sulfonylureas or insulin, making it a safe option for many individuals. More information on diabetes management is available from the MedlinePlus.

How It Works

After oral administration, Metsmall 1000 SR releases metformin slowly along the gastrointestinal tract. The drug inhibits hepatic gluconeogenesis by down‑regulating the expression of enzymes involved in glucose production. Simultaneously, it enhances peripheral glucose uptake through increased insulin‑stimulated glucose transport (GLUT‑4) activity in muscle and adipose tissue. The gradual release profile maintains therapeutic levels for up to 24 hours, which helps to smooth out post‑prandial glucose spikes and reduces the frequency of glucose excursions. This mechanism also contributes to modest weight neutrality and does not stimulate insulin secretion, distinguishing it from other oral hypoglycaemic agents. For an in‑depth review, see the U.S. Food and Drug Administration (FDA) guidance.

Dosage Guidelines

Typical initiation of Metsmall 1000 SR involves one tablet daily with the evening meal, providing 1000 mg of metformin. The dose may be titrated upward based on glycaemic response and tolerability, with a common target of 2000 mg per day (two tablets) divided across the day, if clinically appropriate. Physicians may adjust the dose in patients with renal impairment, starting at a lower strength and monitoring kidney function regularly. It is essential to take the tablet whole, without crushing or chewing, to preserve the sustained‑release characteristics. Patients should be advised to maintain consistent dosing schedules and to avoid missed doses; if a dose is forgotten, it should be taken as soon as remembered unless it is close to the time of the next dose. Additional dosing recommendations are outlined in clinical practice guidelines from the NIH.

Side Effects

Most individuals tolerate Metsmall 1000 SR well, but some may experience gastrointestinal symptoms such as nausea, abdominal discomfort, diarrhea, or a metallic taste. These effects are generally mild and tend to diminish with continued use or dose adjustment. Less commonly, metformin can cause lactic acidosis, a rare but serious condition that requires immediate medical attention; risk factors include severe renal dysfunction, hepatic disease, or conditions that cause tissue hypoxia. Rare hematologic abnormalities, such as decreased vitamin B12 levels, have also been reported, potentially leading to anemia or neuropathy if left untreated. Patients should be instructed to report persistent gastrointestinal distress, unexplained fatigue, or signs of lactic acidosis, such as rapid breathing or muscle pain, to their healthcare provider promptly. For authoritative safety data, refer to the FDA safety communication.

Warnings and Precautions

Metsmall 1000 SR is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, or known hypersensitivity to metformin or any component of the formulation. Caution is advised in individuals with hepatic disease, heart failure, or conditions predisposing to hypoxia, such as respiratory infections. The medication should be temporarily discontinued prior to undergoing radiographic studies involving iodinated contrast due to the potential for renal dysfunction. Pregnant or breastfeeding women should consult a physician before use, as metformin crosses the placenta and is excreted in milk. Routine monitoring of renal function, vitamin B12 status, and glycemic control is recommended throughout therapy. For comprehensive prescribing information, see the product label on the Dr Reddy’s official site.

Frequently Asked Questions